How to buy Biocept shares | $4.38
Own Biocept shares in just a few minutes.
Biocept, Inc is a diagnostics & research business with stocks listed in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$4.38 – an increase of 21.33% over the previous week.
How to buy shares in Biocept
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Biocept. Find the share by name or ticker symbol: BIOC. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biocept reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$4.38, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Biocept, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Biocept. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted Biocept's share price?
Since the stock market crash in March caused by coronavirus, Biocept's share price has had significant positive movement.
Its last market close was US$4.38, which is 92.53% up on its pre-crash value of US$0.327 and 1,973.86% up on the lowest point reached during the March crash when the shares fell as low as US$0.2112.
If you had bought US$1,000 worth of Biocept shares at the start of February 2020, those shares would have been worth US$982.68 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$14,590.26.
Biocept share priceUse our graph to track the performance of BIOC stocks over time.
Biocept shares at a glance
|Latest market close||USD$4.38|
|52-week range||USD$0.2112 - USD$4.85|
|50-day moving average||USD$7.4374|
|200-day moving average||USD$5.5019|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.631|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Biocept stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Biocept price performance over time
|1 week (2020-09-11)||21.33%|
|1 month (2020-08-18)||380.05%|
|3 months (2020-06-18)||361.05%|
|6 months (2020-03-18)||1,725.00%|
|1 year (2019-09-18)||400.40%|
|2 years (2018-09-18)||47.47%|
|3 years (2017-09-18)||242.19%|
|5 years (2015-09-18)||89.61%|
|Revenue TTM||US$5.7 million|
|Gross profit TTM||US$-5,448,954|
|Return on assets TTM||-56.44%|
|Return on equity TTM||-133.91%|
|Market capitalisation||US$48.4 million|
TTM: trailing 12 months
Shorting Biocept shares
There are currently 4.9 million Biocept shares held short by investors – that's known as Biocept's "short interest". This figure is 71.7% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting Biocept shares can be evaluated.
Biocept's "short interest ratio" (SIR)
Biocept's "short interest ratio" (SIR) is the quantity of Biocept shares currently shorted divided by the average quantity of Biocept shares traded daily (recently around 37.9 million). Biocept's SIR currently stands at 0.13. In other words for every 100,000 Biocept shares traded daily on the market, roughly 130 shares are currently held short.
However Biocept's short interest can also be evaluated against the total number of Biocept shares, or, against the total number of tradable Biocept shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biocept's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biocept shares in existence, roughly 20 shares are currently held short) or 0.0237% of the tradable shares (for every 100,000 tradable Biocept shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biocept.
Find out more about how you can short Biocept stock.
Biocept share dividends
We're not expecting Biocept to pay a dividend over the next 12 months.
Have Biocept's shares ever split?
Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.
Biocept share price volatility
Over the last 12 months, Biocept's shares have ranged in value from as little as US$0.2112 up to US$4.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.636. This would suggest that Biocept's shares are less volatile than average (for this exchange).
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Frequently asked questions
Ask an Expert